Morgan S. Levy, MD, MPH

New account | PGY2 @RadoncUK '29 | @S_W_R_O Communications | #gyncsm, #bcsm, brachytherapy, survivorship, menopause after radiation |
@ummdmph | views = mine

[Morgan S. Levy, MD, MPH @MLevyMDMPH]

Would oncologists prescribe hormonal therapy after chemoradiotherapy for cervical cancer?

Out today in @JAMANetworkOpen, our survey through @SGO_org and @AmericanBrachy found that 93% of oncology clinicians would prescribe hormonal therapy but face barriers to implementation in practice.

Read the paper at: https://t.co/dViqQWzNc4

@Deniskafab @DrMarilynHuang #gyncsm

1/3

[Eric K. Singhi, MD @lungoncdoc]

Our new publication on social media & lung cancer education:

▫️70% reported a behavior change
▫️67% more confident discussing care
▫️45% discussed trials in clinic

But, 41% also questioned/delayed medical recs because of conflicting online content.

https://t.co/HubmrCN6pk

[UK RadOnc @RadoncUk]

Congratulations to Dr. Levy (@MLevyMDMPH) for continuing to serve as the National Communications Chair for the Society for Women in Radiation Oncology (@S_W_R_O) this year! ☢️🎉👩🏻‍⚕️

[Morgan S. Levy, MD, MPH @MLevyMDMPH]

“We need a menopause revolution in this country. Better training is an obvious place to start. By including menopause care in both foundational and continuing education for health care practitioners, we can equip more of them to support their patients.”

Thank you @melindagates for your powerful words and investment for the future of menopause care in our country!

In radiation oncology, many patients experience abrupt, early onset menopause, as a direct result of their cancer treatment. Yet, education about radiation induced menopause is not a standard part of training. Without the proper education, it is impossible to provide guideline concordant care. This national cancer survivorship month is an important moment to raise awareness of this key educational opportunity.

Article: https://t.co/Jjr4xYn03u

@Deniskafab #gyncsm #survivorship

[Morgan S. Levy, MD, MPH @MLevyMDMPH]

@RakshaNara @IOgobuiro @CrystalSeldon @ArenSainiMD Congrats Raksha!

[Raksha Narasimhan @RakshaNara]

Excited to share our study evaluating survival outcomes and prognostic factors in pN1 breast cancer patients treated with PMRT in the modern era—particularly rewarding to see a project I began as an M1 reach publication.

🔗https://t.co/jkjJZCcqjS

#RadOnc #BreastCancer

[Morgan S. Levy, MD, MPH @MLevyMDMPH]

@RakshaNara @S_W_R_O @Chitra_Parikh @WomeninOnc @WimedicineOrg @ARRO_org @Timileyin__Ojo @belladreyfuss25 @MCWRORes @UM_JMH_Radonc @RadoncUk @DartmouthRadOnc @PennRadOnc @ASTRO_org You have done some great work for SWRO in communications and research so far!!! We are lucky to have you on the team, and you have a bright future ahead. 💕

[SWRO @S_W_R_O]

We are so excited to introduce the SWRO Executive Committee for 2026-2027! Congratulations to all!! 🎉👩‍⚕️👩🏻‍⚕️👩🏽‍⚕️👩🏾‍⚕️👩🏿‍⚕️👩🏼‍⚕️☢️

#radonc #womeninmedicine @Chitra_Parikh @WomeninOnc @WimedicineOrg

[NRG Oncology @NRGonc]

June is #CancerSurvivorsMonth, a time to honor cancer survivors whose courage & resilience inspire us every day. Their experiences underscore the importance of continued #clinicaltrial research to improve outcomes & quality of life for patients now & in the future.

[UK RadOnc @RadoncUk]

Out today, evaluating FAP immunoreactivity as a potential triage biomarker to identify women with uterine cervix cancer who may benefit from targeted radiopharmaceutical treatment. ☢️

Congrats to Dr. Fabian and Dr. Levy!

Link: https://t.co/0UBO3M9lpZ

@Deniskafab @MLevyMDMPH

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

The most important paper of #ASCO26 just dropped in Nature Med! Or any other @asco or @myESMO meetings to be honest. When you hear someone present “the toxicities were acceptable”, please respond “downplaying toxicities is not acceptable”. Thank you @NatureMedicine for publishing this piece.

https://t.co/ydAfoTWVJ0

[Coral Olazagasti, MD @COlazagasti]

To improve lung cancer screening uptake, we must simplify the process.

Too many barriers exist.

One practical place to start is by making eligibility easier to understand.

#lungcancerscreening @ASCO

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK radiation oncologist Dr. Luke Pike (@pike_lab) presented findings aimed at improving the early detection of brain metastases in #breastcancer. #ASCO26

[SWRO @S_W_R_O]

Reminder! Join SWRO on June 10th for “The Business of Medicine” featuring Madhu Shetti, MD, MBA and Winnifred Wong, DO, MBA. Learn about healthcare finance, physician contracts, and building a financially stable career.

Register at: https://t.co/JewXiIXWpQ

#RadOnc

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

This #ASCO26 RCT is now live @JAMANetworkOpen today! Many congrats to the study team for achieving better outcomes for community dwelling high risk patients with advanced cancer and high symptom burden. @ASCO

➡️ https://t.co/Aj0VRswoof

[ASTRO @ASTRO_org]

June 1 is National Cancer Survivors Day, and we honor cancer survivors today and every day while recognizing the strength behind every journey. 💙

Read patient stories and learn more about radiation therapy on RT Answers.

Explore their stories: https://t.co/B1iXrVasdo

@RTAnswers_org #NationalCancerSurvivorsDay #CancerSurvivorsDay

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

TBCRC-053 PRAD shows interesting proof of concept for preoperative immune-priming RT with pembrolizumab #ASCO26 @OncoAlert

[Paolo Tarantino @PTarantinoMD]

Promising results from the TNBC cohort of P-RAD: the addition of preoperative RT + pembro led to significantly increased T-cell infiltration and descriptively higher pCR rate c/w pembro alone. #ASCO26 @TheTBCRC

[TwoOncDocs @TwoOncDocs]

🚨 first up #PROTEUS Phase 3

Adding peri-op apalutamide to ADT significantly improves outcomes for high-risk localized prostate cancer undergoing surgery:

🔹 pCR/MRD: 8.9% vs 1.0% (10x OR!)

🔹 5-y MFS: 78.2% vs 73.5% (HR 0.80)

⚠️ 8% more gr3/4 tx AEs

#ProstateCancer #ASCO26

[Mark Lewis, MD, FASCO @marklewismd]

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer

Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived

#ASCO26